Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction – findings from the LATITUDE–TIMI 60 trial

American Heart Journal(2022)

引用 4|浏览39
暂无评分
摘要
Patients with STEMI treated with losmapimod had an attenuated inflammatory response. Our collective findings raise the hypothesis that mitigating the inflammatory response may result in different outcomes in patients with STEMI and NSTEMI. While the difference in outcomes is exploratory, these findings do support separate examination of patients with STEMI and NSTEMI and increased emphasis on heart failure in future investigation of modulators of inflammation in MI.
更多
查看译文
关键词
Coronary Artery Disease,Inflammation,Pharmacology,ST-Elevation Myocardial Infarction,acute coronary syndromes,inflammation,losmapimod,myocardial infarction, NCT02145468, clinicaltrials.gov,p38 MAP kinase
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要